Sign in
WithdrawnPhase 2

Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer

Key facts

Who runs it
Inova Health Care Services
Where
Falls Church, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
19 Sept 2025
Ended
19 Sept 2025
Type of study
Interventional
Treatments tested
  • Biweekly 5-FLUOROURACIL (5-FU)
  • Biweekly Modified FOLFOX6
  • Biweekly FOLFIRI
  • mFOLFOXIRI
Record updated
11 February 2026
Why it stopped
Principal Investigator has left Inova

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Males or females at least 18 years of age
  • Histologically confirmed metastatic colorectal cancer eligible for treatment with 5-FU
  • No prior therapy for metastatic disease. If adjuvant 5-FU or FOLFOX was administered, the last dose must have been at least 6 months prior to the diagnosis of metastatic disease
  • Adequate organ function
  • Eastern Cooperative Oncology Group (ECOG) status less than or equal to 2
  • Life expectancy > 3 months

Who cannot take part

  • Untreated brain metastasis. Treated brain metastases are allowed as long as symptoms have resolved off of steroids
  • At least 4 weeks from any prior surgery or 2 weeks from radiation treatments
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency

Where in United States

  • Inova Health Care ServiceFalls Church, United States

About the trial

What the trial wants to find out

The purpose of this research is to see if adjusting the dose of 5-fluorouracil based on its concentration in your blood will improve the treatment of your metastatic colon cancer.

The group in the trial

  • Chemotherapy with 5-FU/Leucovorin (LV) alone, with oxaliplatin or irinotecan or bothTreatment being tested

    Plasma specimens will be collected for the measurement of plasma 5-FU level from patients receiving 5-FU/LV alone, with oxaliplatin (mFOLFOX6) or irinotecan (FOLFIRI), or both (mFOLFOXIRI) chemotherapy. 5-FU doses will be modified based on the assay results.

    Treatment: Biweekly 5-FLUOROURACIL (5-FU), Biweekly Modified FOLFOX6, Biweekly FOLFIRI, and mFOLFOXIRI

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study of Pharmacokinetically (PK) Dose Adjusted 5-Fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Record updated
11 February 2026